1 / 71

France Biosimilars Market Analysis Sample Report

France's biosimilars market size was valued at $0.5 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 21.4% from 2022 to 2030 and will reach $2.4 Bn in 2030. The market is segmented by product type and indication type. The France Biosimilars market will grow with the increased incidence of chronic illnesses, rising healthcare expenses, and the demand for affordable biologic medicine substitutes. To get a detailed report, contact us at - info@insights10.com

Insights4
Download Presentation

France Biosimilars Market Analysis Sample Report

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A sample report on France Biosimilars Market Analysis

  2. This report presents a strategic analysis of the France Biosimilars Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the France Biosimilars Market, and offers unmatched value, accuracy, and expert insights.

  3. Report Scope Report Attribute Details Number of Pages 70-80 Base Year for Estimation 2022 Forecast Period 2023-2030 Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario Report Coverage Quantitative Units Revenue in USD Million/Billion (Mn/Bn) Research Approach Secondary Research (60%), Primary Research (40%) Click on the icon to know the detailed methodology 3 A Sample Report on France Biosimilars Market Analysis I Confidential

  4. Table of Content CONTENT PG. NO. 07-13 1. Biosimilars Market Overview 1.1. Overview 1.2. France Overview 1.3. Economic Overview: France 1.4. Biosimilars Market in France 1.5. Biosimilars Scenario in France 14-19 2. Market Size and Forecasting 2.1. Market size and forecasts (Excel and Methodology) 2.2. Market Segmentation 2.2.1. By Indication 2.2.2. By Distribution Channel 2.2.3. By Route of Administration 4 A Sample Report on France Biosimilars Market Analysis I Confidential

  5. Table of Content CONTENT PG. NO. 20-24 3. Market Dynamics 3.1. Market Growth Drivers 3.2. Market Restraints 25-34 4. Competitive Landscape 4.1. Major Market Share 4.2. Key Company Profile 4.2.1. Pfizer 4.2.2. Celltrion 4.2.3. Amgen 4.2.4. Sandoz 4.2.5. Mylan 4.2.6. Teva 5 A Sample Report on France Biosimilars Market Analysis I Confidential

  6. Table of Content CONTENT PG. NO. 4.2.7. Samsung Bioepis 4.2.8. Biogen 4.2.9. Fresenius Kabi 4.2.10. Merck 35-39 5. Pricing & Reimbursement 5.1. Reimbursement Regulation in France 5.2. Reimbursement Process 40-71 6. Methodology & Scope 6 A Sample Report on France Biosimilars Market Analysis I Confidential

  7. France Biosimilars Market Analysis 1. Market Overview

  8. 1.1 Biosimilars Overview Biosimilars are biological medications that are highly similar to an FDA-approved biologic currently on the market, known as a reference product and differ in no clinically significant ways ▪ Biosimilars mimic the reference product's structure, biological activity, effectiveness, safety, and immunogenicity profile as closely as possible ▪ Process of developing and approving biosimilars is more stringent than that of generic medications as they are manufactured using living cells ▪ Here are some common types of biosimilars based on their biological composition: Type Application Use Monoclonal Antibody Biosimilars Aids the body’s immune system to fight infections Cancer, autoimmune diseases, etc Peptide and Protein Biosimilars Play an important role in multiple functions of the body Diabetes, Anemia, etc G-CSF Biosimilars Stimulates the production of WBCs Neutropenia EPO Biosimilars Stimulates the production of RBCs Anemia

  9. 1.1 Biosimilars Scenario in the World Regional Analysis France Market ~$xx Bn Market ➢ Africa: $ __ ➢ APAC: $ __ ➢ Europe: $ __ ➢ LATAM: $ __ ➢ North America: $ __ Illustrative Illustrative 9 A Sample Report on France Biosimilars Market Analysis I Confidential

  10. 1.2 France Overview Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ $2,782.9 Bn Is the Gross Domestic Product in France in 2022 64.79 Mn Population of France in 2023 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 42 years Is the median age in France $ 4,769 Health expenditure per person in France in 2022 Illustrative Illustrative 10 A Sample Report on France Biosimilars Market Analysis I Confidential

  11. 1.3 Economic Overview: France Population of France, (2020-2030) GDP of France, (2020-2030) XX XX XX XX 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F Population Split (2023) In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ By Gender By Age Group In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 0-14 15-24 25-54 55-64 65+ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Male 49% Female 51% Illustrative Illustrative 11 A Sample Report on France Biosimilars Market Analysis I Confidential

  12. 1.4 Statistics at a Glance: Biosimilars Market in France Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic in France ▪ 80% Market Penetration of Biosimilars in a hospital setting in France in 2021 3% Market Share of Biosimilars of the total Pharmaceutical Market in France In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 80% Market Penetration Target for Biosimilars in France by 2025 48% Market Share of Biosimilars of the total Biological Market in France Illustrative Illustrative 12 A Sample Report on France Biosimilars Market Analysis I Confidential

  13. 1.5 Biosimilars Scenario in France ➢ Prescribing and Use: In order to save healthcare costs, medical practitioners in France are urged to prescribe biosimilars in place of reference biologic products ➢ Regulation and Approval: The European Medicines Agency (EMA) oversees biosimilars in France on the European level. A biosimilar may be sold in France after receiving European approval ➢ Market Share: As healthcare providers and institutions use biosimilars to reduce treatment costs, the market share of biosimilars in France has been rising, especially for biologics that are often prescribed ➢ Education and Awareness: Efforts to enlighten patients, healthcare providers, and the general public about biosimilars are still underway in France ➢ Reimbursement: Particular reimbursement guidelines are in place in the public and private sectors of the French healthcare system to promote the use of biosimilars and keep costs under control ➢ Challenges: Some patients and healthcare professionals may continue to have concerns regarding switching from reference biologics to biosimilars because of concerns about efficacy differences, interchangeability, and trust Illustrative Illustrative 13 A Sample Report on France Biosimilars Market Analysis I Confidential

  14. France Biosimilars Market Analysis 2. Market Size and Forecasting

  15. 2.1 Market size and forecasts (Excel and Methodology) France Biosimilars Market Forecast, 2022-2030 Click on the icon to know the methodology and assumption XX Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ XX In this section you will get an understanding of the overall market, which includes the market size, current trends and other details related to the topic ▪ 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 2023 2024 2025 2026 2027 2028 2029 2030 Major Markets Patient ($Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ France Patient Size ($Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73 % of Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45% Global Market Size ($Bn) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937 France Market Size ($Bn) 61 74 84 87 91 95 99 106 Illustrative Illustrative 15 A Sample Report on France Biosimilars Market Analysis I Confidential

  16. 2.2 Snapshot of Biosimilars Market Segmentation Indication Distribution Channel Route of Administration Oncology Hospital Pharmacies Intravenous Autoimmune Diseases Retail Pharmacies Subcutaneous Hematology Direct-to-Patient Pharmacies Topical Endocrinology Online Pharmacies Others Infectious Diseases Others In this section you will get an understanding of the segmentations which will cover the France Biosimilars Market ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Illustrative Illustrative 16 A Sample Report on France Biosimilars Market Analysis I Confidential

  17. 2.2.1 Market Segmentation: By Indication Oncology is the largest segment for biosimilars in France and it had a market value of more than 40% in 2021 ▪ France Biosimilars Market Share, By Indication (2022) Use of biosimilars for Oncology is growing rapidly due to factors the high prevalence of cancer and the availability of a large number of biosimilars for cancer treatment ▪ Others Infectious Diseases Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Oncology Endocrinology In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Hematology Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic ▪ Autoimmune Diseases Illustrative Illustrative 17 A Sample Report on France Biosimilars Market Analysis I Confidential

  18. 2.2.2 Market Segmentation: By Distribution Channel Most commonly used distribution channel for biosimilars is hospital pharmacies, as biosimilars are usually administered in hospitals making it convenient for patients to procure them from the hospital pharmacy ▪ France Biosimilars Market Share, By Distribution Channel (2022) Online Pharmacies Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Hospital Pharmacies Direct-to-Patient Pharmacies In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Retail Pharmacies Illustrative Illustrative 18 A Sample Report on France Biosimilars Market Analysis I Confidential

  19. 2.2.3 Market Segmentation: By Route of Administration Intravenous biosimilars account for the largest share of the biosimilar market in France ▪ France Biosimilars Market Share, By Route of Administration (2022) Also, subcutaneous biosimilars are gaining popularity due to the ease of self- administration ▪ Others Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Topical Intravenous In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic ▪ Subcutaneous Illustrative Illustrative 19 A Sample Report on France Biosimilars Market Analysis I Confidential

  20. France Biosimilars Market Analysis 3. Market Dynamics

  21. 3.1 Market Growth Drivers 3.1.1 Rising prevalence of chronic diseases in France with more than 20 Mn people suffering from at least one chronic disease Prevalence of chronic diseases is increasing in France owing to reasons like an aging population, increased exposure to environmental risk factors, unhealthy lifestyles, etc ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 21 A Sample Report on France Biosimilars Market Analysis I Confidential

  22. 3.1 Market Growth Drivers (Continued) 3.1.2 Increasing demand for more affordable treatment options due to rising healthcare costs, with about 14% of the French population having difficulty in affording healthcare Out-of-pocket healthcare spending in France was reported to account for 19.5% of the total healthcare spending ▪ As biosimilars are more affordable compared to reference biologics, it has started gaining popularity as the preferred treatment option for patients and payers in France ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2010 2022 2030 Illustrative Illustrative 22 A Sample Report on France Biosimilars Market Analysis I Confidential

  23. 3.1 Market Growth Drivers (Continued) 3.1.3 Government initiatives, with the French government setting a target of 80% biosimilar penetration by 2025 Government in France is extending support for the use of biosimilars through its numerous initiatives including a reimbursement system favoring biosimilars over reference biologics and providing financial support for biosimilar research and development ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 23 A Sample Report on France Biosimilars Market Analysis I Confidential

  24. 3.2 Market Restraints 3.2.1 Competition from alternative products like reference biologics 3.2.3 Lack of awareness of biosimilars 3.2.2 Complex regulatory process for biosimilars in France Only 15% of rural doctors in France expressed willingness to prescribe biosimilars over reference biologics Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Average approval time for a biosimilar in France is 27 months, which delays the launch of new biosimilars Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ ▪ ▪ ▪ ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ ▪ ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic Illustrative Illustrative ▪ Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth. 24 A Sample Report on France Biosimilars Market Analysis I Confidential

  25. France Biosimilars Market Analysis 4. Competitive Landscape

  26. 4.1 Major Market Share Revenue of Major players in the France Biosimilars Market ($ Mn) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Company 10 In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ Company 9 Company 8 Company 7 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Company 6 Company 5 Company 4 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Company 3 Company 2 Company 1 Illustrative Illustrative 26 A Sample Report on France Biosimilars Market Analysis I Confidential

  27. 4.2 Key Players in France Biosimilars Market Key Note: Here is the list of top 10 companies which will cover in the final report ▪ 1 6 Pfizer Teva Each company will have slides for ▪ Overview Key details Offerings Name of products Recent activities/ Press Coverage Distribution and Vendor Partners Mergers, Acquisitions and Collaboration Financials (As per availability) If there are specific companies that you would like to be included in the report, please let us know via email In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Illustrative Illustrative o o 2 7 Celltrion Samsung Bioepis o o o 3 8 Amgen Biogen o o o 4 9 Sandoz Fresenius Kabi ▪ ▪ 10 5 Mylan Merck 27 A Sample Report on France Biosimilars Market Analysis I Confidential

  28. 4.2.1 Pfizer Solutions offered Founded in: 1849 ▪ Pfizer is a leading global pharmaceutical company which is one of the dominant player in the French biosimilars industry ▪ It is committed to developing and commercializing premium biosimilars that are safe, effective as well as affordable ▪ It is investing significantly in the development of novel biosimilars with over 20 of them in development across a variety of therapeutic categories HQ: New York, USA ➢ Diagnostics ➢ Biologics and Biosimilars Type: Private ➢ Pharmaceuticals Revenue: $100.3 Bn (global) ➢ Veterinary products Website: www.pfizer.com Recent Activity / Press Coverage Some of the Biosimilars offered by Pfizer Inflectra (Infliximab) Treatment of Crohn’s disease, etc Oct 2023: Pfizer has recently received FDA approval for its biosimilar ABRILADA™, which is one of only two biosimilars that are interchangeable with Humira® Trazimera (Trastuzumab) Treatment of Breast and Stomach Cancer Oct 2023: Pfizer announced positive topline data for their mRNA- based combination vaccine program against influenza and COVID-19 Rixathon (Rituximab) Treatment of Rheumatoid arthritis Oct 2023: Pfizer France Head Reda Guiha was questioned by the Senate's committee of enquiry into drug shortages Zirabev (Bevacizumab) Treatment of Cancer Illustrative Illustrative 28 A Sample Report on France Biosimilars Market Analysis I Confidential

  29. 4.2.1 Pfizer (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Pfizer announced that it would acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines ▪ This acquisition is expected to enhance Pfizer's position the segment of Oncology, with Seagen's medicines, late-stage development programs, and pioneering expertise in Antibody- Drug Conjugates (ADCs) strongly complementing Pfizer's Oncology portfolio ▪ Acquisition $43 Bn Mar, 2023 Seagen Inc. Pfizer acquired Arena Pharmaceuticals, a clinical-stage startup creating novel potential treatments for the treatment of various immuno-inflammatory illnesses ▪ Acquisition $6.7 Bn Mar, 2022 This acquisition granted Pfizer access to Arena's portfolio of potential treatments for the fields of gastrointestinal, dermatology, and cardiology ▪ Arena Pharmaceuticals Illustrative Illustrative 29 A Sample Report on France Biosimilars Market Analysis I Confidential

  30. 4.2.1 Pfizer (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2023 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 Illustrative Illustrative 30 A Sample Report on France Biosimilars Market Analysis I Confidential

  31. 4.2.2 Company 2 Solutions offered by Company Founded in: HQ: Type: Revenue: Website: Biosimilars Products Recent Activity / Press Coverage Drugs Indications 31 A Sample Report on France Biosimilars Market Analysis I Confidential

  32. 4.2.2 Company 2 (continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners 32 A Sample Report on France Biosimilars Market Analysis I Confidential

  33. 4.2.2 Company 2 (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers 33 A Sample Report on France Biosimilars Market Analysis I Confidential

  34. 4.2.2 Company 2 (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ xx xx xx In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 34 A Sample Report on France Biosimilars Market Analysis I Confidential

  35. France Biosimilars Market Analysis 5. Reimbursement Scenario

  36. 5.1 Reimbursement Regulation for Biosimilars in France Coverage Penetration (% Total Population) Source of Funding Spend on Healthcare (%of Current Health Expenditure) 100% 100% 100% 100% 100% 44.0% Government Expenditure 46.0% xx 47.7% xx xx xx 51.0% 51.8% xx Public Healthcare Coverage Private Health Insurance Out of Pocket 38.9% 37.1% 35.6% 31.5% 32.5% Private Coverage Other NA NA 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6%  Public healthcare coverage is provided by the government and includes various programs GDP Growth (yoy) 14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy) Reimbursement Market Trends ▪ Shift towards value-based care has been a significant trend in France healthcare system, with payers and providers increasingly focused on improving patient outcomes and reducing costs ▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which incentivize providers to deliver high-quality, cost-effective care Illustrative Illustrative 36 A Sample Report on France Biosimilars Market Analysis I Confidential

  37. 5.2 Reimbursement Process The reimbursement process in France healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process: Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient ▪ Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service provided ▪ Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential errors or fraud ▪ Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service provided, based on the negotiated payment rates or fee schedule ▪ Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost of the service, such as deductibles, co-payments, or co-insurance In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 37 A Sample Report on France Biosimilars Market Analysis I Confidential

  38. 5.2 Reimbursement Process (Continued) The reimbursement process in France healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process: MoH Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient ▪ Market Authorization Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service provided ▪ Private Payers Public Payers Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential errors or fraud ▪ Health Technology Assessment Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service provided, based on the negotiated payment rates or fee schedule ▪ 1 2 3 Coding Coverage Payment Coding depends on availability code while coverage and payment process decisions are made through an HTA. Illustrative Illustrative 38 A Sample Report on France Biosimilars Market Analysis I Confidential

  39. France Biosimilars Market Analysis 6. Methodology & Scope

  40. A division of

  41. Life-sciences Market Research Reports you can trust Insights10 is a healthcare focused market research firm founded with an aim of being an insights driven company in the data driven world and delivering actionable insights that can drive decision and strategy making process for businesses www.insights10.com www.insights10.com

  42. Get actionable insights to take informed business decisions A large database of over 30,000 syndicated market research reports in pharmaceuticals and healthcare sector at global, regional as well as country level. We also provide customized research reports tailor made to suit your needs www.insights10.com

  43. Elevate your business plans with in-depth market analysis and industry intelligence Our qualitative, acute, and result-oriented market research reports provide a comprehensive understanding of the business scenario and the latest trends related to the life-sciences market www.insights10.com

  44. Gain a competitive edge with Insights10's customized healthcare research solutions Whether you are looking to expand into new areas, develop new products, or take advantage of new opportunities we have reports to help you accelerate and improve your plans by identifying unique growth prospects. www.insights10.com

  45. Market Research Reports across various categories Pharma (Diseases & Drugs) Digital Health Medical Devices Healthcare Services OTC & Clinical Trials Rare Diseases Nutraceuticals www.insights10.com

  46. FEATURED REPORS Free Sample Reports across various categories www.insights10.com

  47. What makes us different? 30000+ Life science Market Research Reports 22000+ Country Specific Reports 2000+ 1200+ Reports Published Annually Rare & orphan Disease Reports

  48. 1 6 Market Overview Competitive Landscape Growth Drivers & Growth Restraints Key Company Profiles 2 7 Epidemiology & Disease type Policy & Regulatory Landscape 8 3 insights on insights on which our which our reports are reports are based based 9 4 Market Segmentation Reimbursement Scenario 5 10 Market Opportunities Factors Driving Future Growth

  49. Our Services Syndicates Market Research Reports Customized Market Research Reports Primary Research & Interviews Database Service & KOL Mapping Full-Time Engagement Conference Coverage Competitive Intelligence Regulatory Compliance Yearly Access (Subscription)

  50. Over the years, we have developed an in-depth experience of executing market analysis at global, regional & country specific level in life-sciences. Our team has conducted market research across 62+ global markets in America, Europe, Middle East, Africa and Asia Pacific regions Research Projects Done

More Related